429 related articles for article (PubMed ID: 37427095)
1. How molecular advances may improve the diagnosis and management of PTCL patients.
Drieux F; Lemonnier F; Gaulard P
Front Oncol; 2023; 13():1202964. PubMed ID: 37427095
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.
Wang L; Rocas D; Dalle S; Sako N; Pelletier L; Martin N; Dupuy A; Tazi N; Balme B; Vergier B; Beylot-Barry M; Carlotti A; Bagot M; Battistella M; Chaby G; Ingen-Housz-Oro S; Gaulard P; Ortonne N
Br J Dermatol; 2022 Dec; 187(6):970-980. PubMed ID: 35895386
[TBL] [Abstract][Full Text] [Related]
3. Distinct and overlapping features of nodal peripheral T-cell lymphomas exhibiting a follicular helper T-cell phenotype: a multicenter study emphasizing the clinicopathological significance of follicular helper T-cell marker expression.
Paik JH; Koh J; Han B; Kim S; Lee KR; Lee S; Lee JO; Kim TM; Kim WY; Jeon YK
Hum Pathol; 2023 Jan; 131():47-60. PubMed ID: 36495942
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas.
Yoon SE; Cho J; Kim YJ; Ko YH; Park WY; Kim SJ; Kim WS
Exp Hematol Oncol; 2021 May; 10(1):33. PubMed ID: 33990228
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
6. Markers of Follicular Helper T Cells Are Occasionally Expressed in T-Cell or Histiocyte-Rich Large B-Cell Lymphoma, Classic Hodgkin Lymphoma, and Atypical Paracortical HyperplasiaA Diagnostic Pitfall For T-Cell Lymphomas of T Follicular Helper Origin.
Abukhiran I; Syrbu SI; Holman CJ
Am J Clin Pathol; 2021 Aug; 156(3):409-426. PubMed ID: 33624021
[TBL] [Abstract][Full Text] [Related]
7. Novel targeted therapies in peripheral T cell lymphoma.
Jagadeesh D; Smith MR
Discov Med; 2013 Jun; 15(85):367-78. PubMed ID: 23819951
[TBL] [Abstract][Full Text] [Related]
8. Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine.
Zhang Y; Lee D; Brimer T; Hussaini M; Sokol L
Front Oncol; 2020; 10():898. PubMed ID: 32637355
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma.
Lee YP; Yoon SE; Cho J; Ko YH; Jo H; Kim SJ; Kim WS
Ann Hematol; 2022 Jul; 101(7):1535-1543. PubMed ID: 35639152
[TBL] [Abstract][Full Text] [Related]
10. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Iyer SP; Foss FF
Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas.
Braunstein Z; Ruiz M; Hanel W; Shindiapina P; Reneau JC; Brammer JE
J Pers Med; 2022 Jun; 12(6):. PubMed ID: 35743749
[TBL] [Abstract][Full Text] [Related]
12. Contemporary strategies to improve outcomes for peripheral T-cell lymphoma patients following the failure of first-line therapy.
Kallam A; Armitage JO
Expert Rev Hematol; 2020 Jul; 13(7):745-753. PubMed ID: 32478625
[TBL] [Abstract][Full Text] [Related]
13. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.
Ghione P; Faruque P; Mehta-Shah N; Seshan V; Ozkaya N; Bhaskar S; Yeung J; Spinner MA; Lunning M; Inghirami G; Moskowitz A; Galasso N; Ganesan N; van der Weyden C; Ruan J; Prince HM; Trotman J; Advani R; Dogan A; Horwitz S
Blood Adv; 2020 Oct; 4(19):4640-4647. PubMed ID: 33002132
[TBL] [Abstract][Full Text] [Related]
14. Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper Cell lymphomas (TFH PTCL).
Ma H; O'Connor OA; Marchi E
Semin Hematol; 2021 Apr; 58(2):95-102. PubMed ID: 33906727
[TBL] [Abstract][Full Text] [Related]
15. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H; O'Connor OA; Marchi E
Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
[TBL] [Abstract][Full Text] [Related]
16. Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Wilcox R; Naushad H; Rohr J; Heavican TB; Wang C; Bouska A; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):89-100. PubMed ID: 26319391
[TBL] [Abstract][Full Text] [Related]
17. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
Lunning MA; Horwitz S
Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
19. Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics.
Moroch J; Copie-Bergman C; de Leval L; Plonquet A; Martin-Garcia N; Delfau-Larue MH; Molinier-Frenkel V; Belhadj K; Haioun C; Audouin J; Swerdlow SH; Marafioti T; Gaulard P
Am J Surg Pathol; 2012 Nov; 36(11):1636-46. PubMed ID: 23073322
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
